Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials
Muhammad Abdullah, Husna Irfan Thalib, Mustafa Bin Tahir, Noman Khalid, Ahmad Mushtaq, Muhammad Adil Afzal, Michael D Moore, Nagaraja Sharma, Salman Muddassir, Michael Parker Ayers, Mazen Albaghdadi, Wilbert S Aronow · 2026
Read Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials by Muhammad Abdullah, Husna Irfan Thalib, Mustafa Bin Tahir, Noman Khalid, Ahmad Mushtaq, Muhammad Adil Afzal, Michael D Moore, Nagaraja Sharma, Salman Muddassir, Michael Parker Ayers, Mazen Albaghdadi, Wilbert S Aronow (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13099939.txt.
Description
BackgroundNon-obstructive hypertrophic cardiomyopathy (nHCM) remains a therapeutic challenge, with limited pharmacological options beyond symptomatic management. Mavacamten, a selective allosteric cardiac myosin inhibitor, has shown benefit in obstructive HCM, but its role in nHCM is uncertain.MethodsA systematic search of PubMed, Embase, CENTRAL, and ClinicalTrials.gov was conducted up to November 2025 for placebo-controlled randomized controlled trials (RCTs) enrolling patients with nHCM.
Catalog record
| CREATOR | Muhammad Abdullah, Husna Irfan Thalib, Mustafa Bin Tahir, Noman Khalid, Ahmad Mushtaq, Muhammad Adil Afzal, Michael D Moore, Nagaraja Sharma, Salman Muddassir, Michael Parker Ayers, Mazen Albaghdadi, Wilbert S Aronow |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |